Critical Regulatory Paths to Value Inflection

Duration: 1 hour & 6 minutes

Sign up

If you do not wish to receive any communication from us, you may unsubscribe at any time. Click here to view our privacy policy.

The webinar will discuss the ATMP sector, why it is exciting from a technical point of view and what opportunities there are to utilize new and innovative regulatory pathways to get these medicinal products to market, whilst ensuring that the desire for innovation is balanced with the requirement for a robust commercial strategy.

Our webinar will also explore how such critical path thinking impacts investment decisions and is factored into deal structure.


14:00 Welcome from One Nucleus

  • Alicia Gailliez, One Nucleus

14:05 Regulatory routes for value inflection points

  • Kate Coleman, Director/Principal Consultant, PharmaLex

14:30 Discussion: How does the regulatory regime for cell and gene therapies impact investment decisions?

  • Julian Hitchcock, Of Counsel, Bristows LLP
  • Dominic Schmidt, Partner, Syncona

14:50 Q&A

15:00 Close